The American Joint Committee on Cancer (AJCC) Melanoma
Staging Committee proposed a new staging system for melanoma[1,2]; the final
version and validation of this new staging system were published in 2001.[3,4]
The new staging system has been approved by the AJCC Executive Committee, the
International Union Against Cancer (UICC) TNM Committee, the World Health
Organization Melanoma Program, and the European Organization for Research and
Treatment of Cancer (EORTC) Melanoma Group, and will become official with
publication of the sixth edition of the AJCC Cancer Staging Manual in 2002.
This system represents an important advance in that it identifies significant
prognostic variables in patients with melanoma and validates them in an analysis
of 17,600 patients, making it possible to precisely determine the patient’s
chance for survival. The important prognostic indicators regarding the primary
tumor are now identified as thickness and ulceration (level is an important
indication only for T1primary tumors ≤ 1.0 mm in thickness). For patients
with nodal involvement, the number of metastatic nodes, whether the tumor burden
is microscopic or macroscopic, and ulceration of the primary tumor are important
in prognosis. For patients with metastatic disease, the site of metastasis
(skin, subcutaneous, and/or lymph node vs lung vs other sites) is relevant, as
is whether or not the lactate dehydrogenase (LDH) level is elevated.
The new system takes these factors into account: it incorporates ulceration
of the primary as a prognostic indicator (not previously included), includes
patients with satellites and in-transit lesions in stage III, includes the
number of positive nodes (rather than gross dimensions) and tumor burden in the
substaging within stage III, and adds the site of distant metastases and the
presence of elevated LDH as a prognostic indicator for patients with stage IV
Under the new staging system, survival curves correlate well with stage of
disease (see Figure 1) and subgroupings within each stage allow further
refinement of prognosis (see Table 1). This allows the physician to determine
with precision which patients are at high risk for recurrence, and to counsel
patients about their prognosis and therapeutic options. Based on this important
information, the dilemma being faced by the treating physicians and patients at
high risk for recurrence is what, if any, surgical adjuvant therapy to choose.
Alpha-interferon has direct antitumor activity, and also produces immune
modulatory effects. In patients with metastatic disease, the response rate to
alpha-interferon is approximately 15% to 20%. It is the only drug approved in
the United States for adjuvant therapy of melanoma. It was approved as surgical
adjuvant treatment of patients with a T4 primary (> 4.0 mm in thickness) or
node-positive (stage III) melanoma by the US Food and Drug Administration (FDA)
in 1996. It has not been tested or approved as adjuvant therapy for patients
with stage IV disease.
High-Dose Interferon Studies
The Eastern Cooperative Oncology Group (ECOG) completed a prospective
randomized controlled study of interferon (IFN) alfa-2b vs observation as
surgical adjuvant therapy in 287 patients with melanoma (protocol E1684). The
dose used in this study was the maximum tolerated dose: 20 million IU/m²/d
intravenously (IV) 5 days per week for 4 weeks followed by 10 million IU/m²
three times per week subcutaneously (SC) for 48 weeks. The results showed that
there was a significant prolongation of relapse-free survival and overall
survival in the group receiving IFN alfa-2b. Patients randomized to treatment
with IFN alfa-2b had a 9% improvement in continuous disease-free survival (from
26% to 37%) and an 11% improvement in survival (from 37% to 46%) compared with
patients receiving no further treatment.
Dose modification was required in the majority of patients. Toxicityincluding
constitutional symptoms (fever, chills, flu-like symptoms, fatigue, malaise,
diaphoresis), myelosuppression, hepatotoxicity, and neurologic symptomswas
considerable: 67% of the patients had severe (grade 3) toxicity, 9% had
life-threatening toxicity, and there were two deaths due to hepatotoxicity. It
is important to consider this toxicity in context. These are patients who have
had surgical excision of their melanoma and are clinically free of disease.
Although they are at high risk for recurrence, some of them may already be
cured. This is different from the situation in which one is administering
chemotherapy for widespread metastatic disease, where there is no choice and the
toxicity must be accepted as part of the treatment.
In follow-up, a large, prospective, randomized trial was done by the same
group in a similar patient population (protocol E1690). This study included 642
patients randomized to three arms: high-dose interferon as described above,
low-dose interferon, or observation. The results show that time to disease
progression was prolonged in the patients receiving high-dose interferon, but
overall survival was the same in all three arms, indicating that there was no
survival benefit in patients receiving high-dose interferon.
There has also been a third prospectively randomized trial of high-dose
interferon as adjuvant therapy of high-risk melanoma. This trial, described
below, compared outcome following this therapy with that in patients randomized
to receive a therapeutic melanoma vaccine. The vaccine was based on GM2, a
ganglioside derived from bovine brain, which is overrepresented on melanoma
cells and thus can be used in a vaccine in an effort to stimulate an immune
response to melanoma.
A double-blind randomized trial compared a ganglioside vaccine with bacille
Calmette-Guérin (GM2/BCG) to BCG alone as adjuvant therapy in 122 patients with
stage III melanoma. The results showed improved survival in patients with GM2
antibodies as compared with patients who did not have these antibodies. In a
subsequent phase I trial, it was shown that conjugating the GM2 ganglioside with
keyhole limpet hemocyanin (KLH) and administering it with the saponin adjuvant
QS-21 resulted in serologic responses against GM2 that were strikingly superior,
quantitatively and qualitatively, to any seen with previously tested GM2
These results formed the basis for the trial mentioned above, which was
conducted in a combined protocol by the Eastern Cooperative Oncology Group
(protocol E1694), the Southwest Oncology Group (SWOG, protocol S9512), and
Cancer and Leukemia Group B (CALGB protocol C509801). The study included 880
patients who were randomized to either high-dose interferon or the GM2/KLH
vaccine with QS-21 (called GMK), 774 of which were eligible for efficacy
analysis. The results showed that patients receiving the high-dose interferon
enjoyed benefit in overall and disease-free survival as compared to patients who
received the vaccine. However, the study has been criticized for several
reasons: (1) the median follow-up was short for this patient population (16
months); (2) there was no control group given observation alone; (3) the
difference in overall survival in the two arms was not great (78% for IFN
alfa-2b and 73% for GMK); and (4) the vaccine regimen was changed between the
positive phase II trial and the phase III trial (QS-21 was substituted for BCG).
This might have resulted in an adverse effect on the outcome because of
resultant increased titers of IgG antimelanoma antibody, which might have had a
blocking effect on the cell-mediated immune response to the tumor.
Other groups have also studied interferon as adjuvant therapy of melanoma.
The North Central Cancer Treatment Group (NCCTG) compared high-dose IFN alfa-2a
(20 million IU/m² intramuscularly three times per week for 12 weeks) vs
observation in 262 patients with high-risk melanoma. There was no benefit in
the treated group. The World Health Organization (WHO) evaluated IFN alfa-2a in
444 patients with node-positive melanoma using a dose of 3 million IU/d SC three
times per week for 3 years and found no impact on disease-free or overall
The EORTC conducted a trial (protocol 18871) in parallel with the German
Cancer Society (DKG, protocol 80-1) in which 830 patients with stage II (> 3
mm) or stage III melanoma were randomized to either 1 million IU of IFN alfa-2b
SC every other day for 1 year, IFN-gamma, mistletoe extract (Iscador, available
in the United States as Iscar), or observation. This is a mature study, with
a median follow-up of 5.9 years. The results show no difference in disease-free
or overall survival for the patients treated with IFN alfa-2b as compared with
observation-only controls (patients treated with Iscador actually had a worse
outcome than the controls or interferon-treated patients).
The EORTC has launched a follow-on trial (protocol 18952) in patients with
stage IIB or III melanoma. Patients are randomized to either (1) IFN alfa-2b
at 10 million IU 5 days/wk for 4 weeks SC, then three times/wk for 1 year; (2)
IFN alfa-2b at 10 million IU 5 days/wk for 4 weeks SC, then 5 million IU three
times/wk for 2 years; or (3) observation. So far, 1,418 patients have been
enrolled in the study. At the 2001 meeting of the American Society of Clinical
Oncology, Dr. Eggermont reported that with a median follow-up of 1.9 years,
there was an advantage (P = .04) for the 2-year regimen with very little
toxicity compared with high-dose interferon. The authors conclude that it is too
early to make a determination regarding the impact on overall survival and/or to
draw conclusions regarding this important study.
1. Buzaid AC, Ross MI, Balch CM, et al: Critical analysis of the current
American Joint Committee on Cancer Staging System for cutaneous melanoma and
proposal of a new staging system [see comments]. J Clin Oncol 15:1039-1051,
2. Balch CM, Buzaid AC, Atkins MB, et al: A new American Joint Committee on
Cancer staging system for cutaneous melanoma. Cancer 88:1484-1491, 2000.
3. Balch CM, Buzaid AC, Soong SJ, et al: Final version of the American Joint
Committee on Cancer Staging System for cutaneous melanoma. J Clin Oncol
4. Balch CM, Soong SJ, Gershenwald JE, et al: Prognostic factors analysis of
17,600 melanoma patients: Validation of the American Joint Committee on Cancer
Melanoma Staging System. J Clin Oncol 19:3622-3634, 2001.
5. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b
adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern
Cooperative Oncology Group Trial EST1684 [see comments]. J Clin Oncol 14:7-17,
6. Kirkwood JM, Ibrahim JG, Sondak VK, et al: High- and low-dose interferon
alfa-2b in high-risk melanoma: First analysis of Intergroup trial
E1690/S9111/C9190. J Clin Oncol 18:2444-2458, 2000.
7. Livingston PO, Wong GY, Adluri S, et al: Improved survival in stage III
melanoma patients with GM2 antibodies: A randomized trial of adjuvant
vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994.
8. Livingston PO, Adluri S, Helling F, et al: Phase 1 trial of immunological
adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate
vaccine in patients with melignant melanoma. Vaccine 12:1275-1280, 1994.
9. Kirkwood JM, Ibrahim JG, Sosman JA, et al: High-dose interferon alfa-2b
significantly prolongs relapse-free and overall survival compared with the
GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results
of intergroup trial E1694/S9512/C509801. J Clin Oncol 19:2370-2380, 2001.
10. Creagan ET, Dalton RJ, Ahmann DL, et al: Randomized, surgical adjuvant
clinical trial of recombinant interferon alfa-2a in selected patients with
malignant melanoma. J Clin Oncol 13:2776-2783, 1995.
11. Cascinelli N: Evaluation of efficacy of adjuvant rIFN-alpha-2a in
melanoma patients with regional node metastases (abstract 1296). Proc Am Soc
Clin Oncol 14:410, 1995.
12. Eggermont A: The EORTC melanoma group experience: IFN-alpha2b adjuvant
therapy in stage II-III melanoma phase III trial experience in > 2000 pts.
Proc Am Soc Clin Oncol 20:158, 2001.
13. Grob JJ, Dreno B, Delaunay M, et al: Long-term results of adjuvant
therapy with low dose IFN-a2A in resected primary melanoma thicker than 1.5 mm
without clinically detectable node metastases (abstract 1983). Proc Am Soc Clin
Oncol 17:514a, 1998.
14. Pehamberger H, Soyer HP, Steiner A, et al: Adjuvant interferon alfa-2a
treatment in resected primary stage II cutaneous melanoma. Austrian Malignant
Melanoma Cooperative Group [see comments]. J Clin Oncol 16:1425-1429, 1998.
15. Fidler IJ, Kleinerman ES: Lymphokine-activated human blood monocytes
destroy tumor cells but not normal cells under cocultivation conditions. J Clin
Oncol 2:937-943, 1984.
16. Grabstein KH, Urdal DL, Tushinski RJ, et al: Induction of macrophage
tumoricidal activity by granulocyte-macrophage colony-stimulating factor.
Science 232:506-508, 1986.
17. Thomassen MJ, Barna BP, Rankin D, et al: Differential effect of
recombinant granulocyte macrophage colony-stimulating factor on human monocytes
and alveolar macrophages. Cancer Res 49:4086-4089, 1989.
18. Chachoua A, Oratz R, Hoogmoed R, et al: Monocyte activation following
systemic administration of granulocyte-macrophage colony-stimulating factor. J
Immunother Emphasis Tumor Immunol 15:217-224, 1994.
19. Wing EJ, Magee DM, Whiteside TL, et al: Recombinant human granulocyte/macrophage
colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor
necrosis factor alpha and interferon in cancer patients. Blood 73:643-646, 1989.
20. Young JW, Szabolcs P, Moore MA: Identification of dendritic cell
colony-forming units among normal human CD34+ bone marrow progenitors that are
expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence
of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor
alpha [published erratum appears in J Exp Med 183:1283, 1996]. J Exp Med
21. Szabolcs P, Moore MA, Young JW: Expansion of immunostimulatory dendritic
cells among the myeloid progeny of human CD34+ bone marrow precursors cultured
with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha.
J Immunol 154:5851-5861, 1995.
22. Szabolcs P, Avigan D, Gezelter S, et al: Dendritic cells and macrophages
can mature independently from a human bone marrow-derived, post-colony-forming
unit intermediate. Blood 87:4520-4530, 1996.
23. Kumar R, Dong Z, Fidler IJ: Differential regulation of metalloelastase
activity in murine peritoneal macrophages by granulocyte-macrophage
colony-stimulating factor and macrophage colony-stimulating factor. J Immunol
24. Dong Z, Kumar R, Yang X, et al: Macrophage-derived metalloelastase is
responsible for the generation of angiostatin in Lewis lung carcinoma. Cell
25. Spitler LE, Grossbard ML, Ernstoff MS, et al: Adjuvant therapy of stage
III and IV malignant melanoma using granulocyte-macrophage colony-stimulating
factor [see comments]. J Clin Oncol 18:1614-1621, 2000.
26. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of
melanoma. IV. Prognostic factors in 200 melanoma patients with distant
metastases (stage III). J Clin Oncol 1:126-134, 1983.
27. Balch CM, Soong SJ, Murad TM, et al: A multifactorial analysis of
melanoma. III. Prognostic factors in melanoma patients with lymph node
metastases (stage II). Ann Surg 193:377-388, 1981.
28. Spitler LE, Jacobs M, Weber R, et al: Adjuvant therapy of stage III and
IV melanoma using granulocyte-macrophage colony-stimulating factor (GM-CSF)
(abstract 1429). Proc Am Soc Clin Oncol 20:358a, 2001.
29. Bugelski PJ, Kirsh RL, Poste G: New histochemical method for measuring
intratumoral macrophages and macrophage recruitment into experimental
metastases. Cancer Res 43:5493-5501, 1983.
30. Bugelski PJ, Kirsh RL, Sowinski JM, et al: Changes in the macrophage
content of lung metastases at different stages in tumor growth. Am J Pathol
31. Bugelski PJ, Corwin SP, North SM, et al: Macrophage content of
spontaneous metastases at different stages of growth. Cancer Res 47:4141-4145,
32. Rowe JM, Andersen JW, Mazza JJ, et al: A randomized placebo-controlled
phase III study of granulocyte-macrophage colony-stimulating factor in adult
patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study
of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-462, 1995.
33. Witz F, Sadoun A, Perrin MC, et al: A placebo-controlled study of
recombinant human granulocyte-macrophage colony-stimulating factor administered
during and after induction treatment for de novo acute myelogenous leukemia in
elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM).
Blood 91:2722-2730, 1998.
34. Godwin JE, Kopecky KJ, Head DR, et al: A double-blind placebo-controlled
trial of granulocyte colony-stimulating factor in elderly patients with
previously untreated acute myeloid leukemia: A Southwest Oncology Group study
(9031). Blood 91:3607-3615, 1998.
35. Harousseau JL, Witz B, Lioure B, et al: Granulocyte colony-stimulating
factor after intensive consolidation chemotherapy in acute myeloid leukemia:
Results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues
Myeloblastiques. J Clin Oncol 18:780-787, 2000.
36. Edmonson JH, Long HJ, Kvols LK, et al: Can molgramostim enhance the
antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Ann
Oncol 8:637-641, 1997.
37. Honkoop AH, Luykx-de Bakker SA, Hoekman K, et al: Prolonged neoadjuvant
chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist
38. Small EJ, Reese DM, Um B, et al: Therapy of advanced prostate cancer with
granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5:1738-1744,
39. De Gast GC, Klupen H-J, Vyth-Dreese FA, et al: Phase I trial of combined
immunotherapy with subcutaneous GM-CSF, low dose IL-2 and IFNa in progressive
metastatic melanoma or renal cell carcinoma (abstract 1720). Proc Am Soc Clin
Oncol 18:446a, 1999.
40. O’Day SJ: Maintenance biotherapy with decrescendo interleukin-2 and GM-CSF
for patients with metastatic melanoma following modified concurrent
biochemotherapy. Immune-Enhancing Cytokines 2:6-10, 2000.
41. Hersey P, Coates A, McCarthy WH, et al: Vaccinia melanoma lysates (VMCL)
in immunotherapy of stage IIb and III melanoma. Third International Conference
on the Adjuvant Therapy of Malignant Melanoma. Royal College of Physicians,
London, 1999, pp 1-15.
42. Wallack MK, Sivanandham M, Balch CM, et al: A phase III randomized,
double-blind multi-institutional trial of vaccinia melanoma oncolysate-active
specific immunotherapy for patients with stage II melanoma. Cancer 75:34-42, 1995.
43. Kirkwood JM: ECOG studies of vaccines, past and present. Melanoma Res
44. Legha SS, Ring S, Eton O, et al: Development of a biochemotherapy regimen
with concurrent administration of cisplatin, vinblastine, dacarbazine,
interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin
Oncol 16:1752-1759, 1998.
45. Retsas S, Quigley M, Pectasides D, et al: Clinical and histologic
involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine
improves survival. Cancer 73:2119-2130, 1994.
46. Lissoni P, Brivio O, Brivio F, et al: Adjuvant therapy with the pineal
hormone melatonin in patients with lymph node relapse due to malignant melanoma.
J Pineal Res 21:239-242, 1996.
47. Quirt IC, Shelley WE, Pater JL, et al: Improved survival in patients with
poor-prognosis malignant melanoma treated with adjuvant levamisole: A phase III
study by the National Cancer Institute of Canada Clinical Trials Group [see
comments]. J Clin Oncol 9:729-735, 1991.
48. Spitler LE: A randomized trial of levamisole versus placebo as adjuvant
therapy in malignant melanoma. J Clin Oncol 9:736-740, 1991.